Literature DB >> 1506127

Presentation of results from bioequivalence studies.

R Sauter1, V W Steinijans, E Diletti, A Böhm, H U Schulz.   

Abstract

Based on general guidelines and requirements for the design and analysis of bioequivalence studies, specific recommendations are made for the presentation of results, both in tabular and graphical form. This is done by means of two examples, one of a single-dose study and one of a multiple-dose study. The recommendations in this paper are twofold. Firstly, a complete and rather detailed presentation of results is given, which practically corresponds to the standard of research reports. Secondly, a subset of this is suggested for publication. It gives the essential results for bioequivalence assessment in a standardized form. From an editorial point of view, it would be highly appreciated if the papers submitted for publication were always accompanied by a complete presentation including the individual concentration/time data and the various steps of calculation. This would speed up peer review and ultimately improve and harmonize the standard of bioequivalence publications.

Mesh:

Substances:

Year:  1992        PMID: 1506127

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  12 in total

1.  The existence of sequence effect in cross-over bioequivalence trials.

Authors:  E Zintzaras
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

2.  Estimation of Cmax and Tmax in populations after single and multiple drug administrations.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-10       Impact factor: 2.745

3.  Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation.

Authors:  Anton Drollmann; Ruediger Nave; Volker W Steinijans; Eugen Baumgärtner; Thomas D Bethke
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Age and gender dependent bioavailability of R- and R,S-α-lipoic acid: a pilot study.

Authors:  Dove J Keith; Judy A Butler; Brett Bemer; Brian Dixon; Shawn Johnson; Mary Garrard; Daniel L Sudakin; J Mark Christensen; Cliff Pereira; Tory M Hagen
Journal:  Pharmacol Res       Date:  2012-05-16       Impact factor: 7.658

5.  Comparative pharmacokinetics of two nifedipine products in capsule form following single oral administration in healthy volunteers.

Authors:  N M Rawashdeh; A H Battah; Y M Irshaid; M K al-Qato
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Jul-Sep       Impact factor: 2.441

6.  Pharmacokinetics of carbamazepine. Part I: A new bioequivalency parameter based on a relative bioavailability trial.

Authors:  A Kayali; I Tuğlular; M Ertaş
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Oct-Dec       Impact factor: 2.441

7.  Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin.

Authors:  L Duursema; F O Müller; R Schall; M V Middle; H K Hundt; G Groenewoud; V W Steinijans; H Bliesath
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

8.  Food Inhibits the Oral Bioavailability of the Major Green Tea Antioxidant Epigallocatechin Gallate in Humans.

Authors:  Nenad Naumovski; Barbara L Blades; Paul D Roach
Journal:  Antioxidants (Basel)       Date:  2015-05-27

9.  Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.

Authors:  Rita R Alloway; Alexander A Vinks; Tsuyoshi Fukuda; Tomoyuki Mizuno; Eileen C King; Yuanshu Zou; Wenlei Jiang; E Steve Woodle; Simon Tremblay; Jelena Klawitter; Jost Klawitter; Uwe Christians
Journal:  PLoS Med       Date:  2017-11-14       Impact factor: 11.069

10.  Bioequivalence study of donepezil hydrochloride tablets in healthy male volunteers.

Authors:  Noppamas Rojanasthien; Siriluk Aunmuang; Nutthiya Hanprasertpong; Sukit Roongapinun; Supanimit Teekachunhatean
Journal:  ISRN Pharmacol       Date:  2012-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.